The CD70-targeting CTX131 heads for the scrapheap.
ApexOnco Front Page
Recent articles
Bezuclastinib plus Sutent could become standard of care in second-line GIST.
Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.
Tamarack data reveal vobra-duo’s toxicity, and wipe out the past six months’ share price gains.
But the group’s attempt to join Janux at the high altar of masking technology falls flat.
A tumour-agnostic label for Enhertu leads April’s US oncology approvals.
A phase 2 head and neck trial missed its primary endpoint, but the group is taking heart from survival data.
Hutchmed starts phase 1 with a project in a field where Syndax and Kura have so far been the main players.